Today, we revealed our bold ambition to deliver $80bn in annual revenue by 2030, up from $45bn in 2023. This will be achieved through significant growth in our existing oncology, biopharmaceuticals and rare disease portfolio, and by launching 20 new medicines for patients before the end of the decade. And, to drive sustained growth beyond 2030, we’ll continue investing in, and rapidly advancing, transformative new technologies and platforms that will shape the future of medicine. As we enter a new era of growth, we will continue to decouple carbon emissions from our increase in revenue, halving emissions across our value chain by 2030. #AZN #WhatScienceCanDo
AstraZeneca
Pharmaceutical Manufacturing
Cambridge, Cambridgeshire 2,883,821 followers
What science can do
About us
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
- Website
-
http://www.astrazeneca.com
External link for AstraZeneca
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Cambridge, Cambridgeshire
- Type
- Public Company
- Specialties
- Pharmaceutical, Biopharmaceutical, Innovation, Research and development, and Global business
Locations
-
Primary
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, Cambridgeshire CB2 0AA, GB
-
Astraallen
Sodertalje, Stockholm County 152 57, SE
Employees at AstraZeneca
Updates
-
Cardiovascular diseases including heart failure often coexist with renal disorders such as chronic kidney disease. Understanding and addressing their disease drivers such as hypertension and dyslipidaemia can protect vital organs and improve patient outcomes. Learn more: https://learn.az/6048jW9Iu
-
Chronic obstructive pulmonary disease (COPD) impacts ~391 million people worldwide. There are many disease mechanisms involved in COPD, meaning each individual patient is different. For that reason, we are exploring multiple disease pathways to drive innovation, working to ensure the right care options are available to the right patients, at the right time. Learn more about our efforts in this new STAT article by Caterina Brindicci, Senior Vice President and Global Head of Late Respiratory and Immunology at AstraZeneca https://learn.az/6041dRkFd #WhatScienceCanDo #ATS2024
-
We are excited to announce our plans for a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs). ADCs are a class of drugs designed as a targeted therapy for treating cancer. This new facility will further enhance our world-class supply chain. The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be designed to emit zero carbon from its first day of operations and will be the first end-to-end ADC production site in our global manufacturing and supply network. #Oncology #WhatScienceCanDo
-
From eosinophilic asthma to hypereosinophilic syndrome, elevated eosinophil counts can play a significant role in blood and affected tissue inflammation. This leads to a wide range of negative patient impacts, ranging from fatigue to organ failure and actively participates in the cycle of chronic inflammation and tissue damage observed in various diseases. Join us in uncovering their impact and transforming patient care. Learn more here: https://learn.az/6040dkeOw #WorldEOSDay #EosAware #NEAW
-
Chronic diseases like asthma and COPD are complex and have a significant impact on the lives of millions of people around the world. Many patients continue to face poor disease control, which can increase the risk of hospitalizations and mortality. This rising public health crisis demands our attention and action. As we start this year’s American Thoracic Society International Conference, learn about our ongoing mission in respiratory care and how we are rising to meet the challenge: https://learn.az/6043dRVv1 #WhatScienceCanDo #ATS2024
-
Our Young Health Programme is working to deliver better health choices for brighter life chances. Empowering young people to avoid risk factors can help prevent diseases that can occur later in life. Learn more: https://learn.az/6043dXtjd UNICEF, Plan International #WorldHypertensionDay #HypertensionDay #YoungHealthProgramme
-
It is staggering to think that an estimated 1.3 billion adults around the world are affected by hypertension. Today, on World Hypertension Day, together with healthcare professionals, patients, and communities worldwide, we are raising awareness of the importance of a better hypertension control. To drive progress in a space that has seen little innovation for almost twenty years, we must all do our part to support diagnosis, education and treatment of hypertension. The consequences if left uncontrolled include heart attacks, strokes and even death. Learn more about the global burden of hypertension in this World Health Organization report: https://learn.az/6044dRu5m #WorldHypertensionDay
Global report on hypertension: the race against a silent killer
who.int
-
Our CFO, Aradhana Sarin recently hosted a compelling discussion on her podcast ‘In Conversation with…’ Joined by members of our Senior Executive Team, Sharon Barr, Pam Cheng, Susan Galbraith and Iskra Reic – they shared career advice, addressed the pivotal role of women in leadership and the obstacles women still face in the workplace today. Discover the full episode here: https://learn.az/6046duZve #WhatScienceCanDo #WomenInSTEM
-
We are reflecting on the theme of Learning Power and how we empower our people in their development journeys. Hear from some of our colleagues about their experience of taking part in our leadership programs, supporting them as they grow and develop into future leaders. #LAWW2024